Menu Back to Oligonucleotide-Based-Therapeutics-Conference


The DIA Oligonucleotide-Based Therapeutics Conference fosters open discussion with industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. Designed for regulators and industry from CMC, nonclinical, clinical pharmacology, and clinical disciplines, you will address the developmental advances, safety, and challenges in the field of oligonucleotide-based therapeutics.
What previous attendees have said:

"This conference is a unique opportunity to learn about the latest advances and challenges in the development of oligonucleotide therapeutics, encompassing all aspects of the development process from preclinical to regulatory."

"The event was well organized, the topics well thought out, the presenters were outgoing and interactive, and the assembly of attendees really fit the DIA mission of bringing people with common interests together in a productive way."

Oligonucleotide-Based Therapeutics Conference
Call for Poster Abstracts

Abstract Submission Deadline: Monday, July 22

Read Abstract Details | Submit


  • Clinical Track
  • Nonclinical Track
  • CMC Track

  • Program Committee

    • Arthur A. Levin, PhD
      Arthur A. Levin, PhD Executive Vice President, Research and Development
      Avidity Biosciences , United States
    • Emily J. Place, PhD, MPH
      Emily J. Place, PhD, MPH Pharmacologist, Office of New Drugs, CDER
      FDA, United States
    • Ramesh  Raghavachari, PhD
      Ramesh Raghavachari, PhD Chief, Branch I, DPMA1, OLDP, OPQ, CDER
      FDA, United States
    • Paul C. Brown, PhD
      Paul C. Brown, PhD ODE Associate Director for Pharmacology and Toxicology, OND, CDER
      FDA, United States
    • Daniel  Capaldi, PhD
      Daniel Capaldi, PhD Vice President, Analytical and Process Development
      Ionis Pharmaceuticals, Inc., United States
    • Xuan  Chi, MD, PhD
      Xuan Chi, MD, PhD Pharmacologist/Toxicology Reviewer, Div. of Cardiovascular & Renal Products, OND
      FDA, United States
    • Scott  Henry, PhD
      Scott Henry, PhD Vice President, Nonclinical Development
      Ionis Pharmaceuticals, Inc., United States
    • Aimee L. Jackson, PhD
      Aimee L. Jackson, PhD Senior Director of Research
      miRagen Therapeutics, United States
    • Arthur M. Krieg, MD
      Arthur M. Krieg, MD Founder and CSO
      Checkmate Pharmaceuticals, United States
    • Saraswathy V. Nochur
      Saraswathy V. Nochur Senior Vice President, Regulatory Affairs & QA
      Alnylam Pharmaceuticals, Inc., United States
    • Louis  O'Dea
      Louis O'Dea
      Radius Health Inc., United States
    • Eugene  Schneider
      Eugene Schneider Vice President
      Ionis Pharmaceuticals, Inc, United States
    • James D. Thompson, PhD
      James D. Thompson, PhD Head, CMC Project Management
      Moderna Therapeutics, United States
    • Barry  Ticho, DrMed, PhD
      Barry Ticho, DrMed, PhD CMO
      Stoke Therapeutics, United States
    • Kim  Tyndall
      Kim Tyndall Consultant
      United States
    • James  Wild, PhD
      James Wild, PhD Pharmacologist, CDER
      FDA, United States
    Load More

    Contact us

    Registration Questions?

    Send Email

    Oligonucleotide-Based Therapeutics Conference
    Call for Poster Abstracts

    Abstract Submission Deadline: Monday, July 22

    Read Abstract Details | Submit

    Digital Learning Catalog

    DIA Learning: eLearning Soultions